Lung Cancer
Conference Coverage
Hypofractionated radiotherapy: New normal for lung cancer?
Almost 20% of lung cancer patients in a U.K. study had their radiotherapy dose or fractionation schedule changed during the first wave of the...
News
List of COVID-19 high-risk comorbidities expanded
Underlying conditions increase the risk of severe outcomes for patients infected with SARS-CoV-2.
Conference Coverage
Technique combines ‘best of both worlds’ to target lung nodules
Bronchoscopic transbronchial microwave ablation proved feasible in a small study.
Conference Coverage
Camrelizumab ‘another brick in the wall’ against squamous NSCLC
Adding camrelizumab to chemotherapy improved survival in patients with squamous non–small cell lung cancer.
Conference Coverage
Can benefits of SBRT outweigh risks in ultra-central lung tumors?
Stereotactic body radiotherapy for ultra-central lung tumors offers good disease control and survival but carries a risk of lung hemorrhage.
Conference Coverage
KRYSTAL-1: Clear activity of adagrasib in KRAS-mutated NSCLC
Phase 1/2 results with adagrasib confirm KRAS G12C as a druggable target in non–small cell lung cancer.
From the Journals
Melatonin not recommended for early-stage NSCLC
There was a hint of benefit with melatonin among patients with stage III/IV NSCLC.
News
Expert recommendations for targeted therapies in advanced NSCLC
The recommendations update guidance from 2017.
News
USPSTF expands criteria for lung cancer screening
The population now eligible for lung cancer screening has more than doubled.
News from the FDA/CDC
Pembrolizumab SCLC indication withdrawn in U.S.
The small cell lung cancer indication had been granted an accelerated approval, but a subsequent confirmatory study showed no survival benefit.